European Unified Patent Court Rules In Favor Of Bruker And NanoString, Invalidating Patent Asserted By 10x Genomics Against NanoString's CosMx SMI Products
Portfolio Pulse from Benzinga Newsdesk
The European Unified Patent Court ruled in favor of Bruker and NanoString, invalidating a patent asserted by 10x Genomics against NanoString's CosMx SMI products. This decision follows a similar ruling by the German Federal Patent Court.
October 17, 2024 | 12:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bruker Corporation's NanoString business won a legal battle in the European Unified Patent Court, invalidating a patent asserted by 10x Genomics. This strengthens NanoString's position in the market.
The invalidation of the patent strengthens Bruker's NanoString business by removing legal obstacles, potentially enhancing market confidence and future sales of CosMx SMI products.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
10x Genomics faced a setback as the European Unified Patent Court invalidated its patent against NanoString's CosMx SMI products. This could impact its competitive position in Europe.
The invalidation of the patent is a legal setback for 10x Genomics, potentially affecting its competitive edge and market strategy in Europe.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80